PDF(999 KB)
PDF(999 KB)
PDF(999 KB)
新生儿缺氧缺血性脑病药物治疗临床证据
Clinical evidence for the pharmacological therapy in newborn infants with hypoxic-is-chemic encephalopathy
目的：药物治疗是缺氧缺血性脑病（hypoxic-ischemic encephalopathy，HIE）治疗的重要组成部分，以循证医学方法为基础的系统评价和临床随机对照试验为判定药物干预疗效提供了最可靠的证据。该研究检索了近年来的HIE药物治疗的临床证据，并探讨其临床应用价值。方法：检索MEDLINE、EMBASE、Oxford围产新生儿组资料库和Cochrane图书馆关于HIE药物治疗的随机（或半随机）对照研究（randomized or quasi-randomized controlled trials, RCT）和系统评价，并进行分析。结果：4个系统评价和13个RCT涉及HIE的药物治疗临床试验。治疗药物包括巴比妥类药物、别嘌呤醇、硫酸镁、甘露醇、纳络酮和多巴胺。上述药物均不能显著降低HIE患儿新生儿期和婴儿期死亡率以及严重神经发育残疾率和惊厥发生率。结论：目前尚未有临床证据表明某种药物能明显降低HIE患儿死亡率及改善神经系统预后。现有HIE药物治疗的临床试验存在规模小，疗效判定方法不统一等问题，需大规模的临床协作试验证实现有药物的有效性。［中国当代儿科杂志，2009，11（9）：740-744］
OBJECTIVE: Pharmacological intervention is an important means for the treatment of hypoxic-ischemic encephalopathy (HIE). As meta-analyses and randomized controlled clinical trials based on evidence-based medicine are able to provide the most reliable evidence for clinical practice, this study searched several databases in order to find the clinical evidence for the pharmacological treatment of neonatal HIE. METHODS: Meta-analyses and randomized (or quasi-randomized) controlled trials (RCT) for pharmacological therapy of HIE in term or late preterm newborn infants were searched from the databases of MEDLINE, EMBASE, Oxford Neonatal Group and Cochrane Library. The relevant literatures were statistically analyzed. RESULTS: Four Meta-analyses and thirteen RCTs were found to be involved in barbiturate, allopurinol, magnesium sulfate, mannitol, naloxone and dopamine therapy. None of the drugs could significantly decrease the mortality and the incidence of seizure or severe neurodevelopmental disabilities in newborn infants with HIE. CONCLUSIONS: Current clinical evidence indicates that no individual drug could decrease mortality and improve the neurodevelopmental outcomes in infants with HIE. Problems such as small scale in sampling and discrepancy in the identification of drug efficacy which exist in the clinical trials might lead to the uncertain effect of the drugs, and large sized and collaborative clinical trials are needed in the future.［Chin J Contemp Pediatr, 2009, 11 (9):740-744］
Hypoxic-ischemic encephalopathy / Clinical evidence / Systemic analysis / Newborn infant
［1］Evans DJ, Levene MI, Tsakmakis M. Anticonvulsants for preventing mortality and morbidity in full term newborns with perinatal asphyxia［J］. Cochrane Database Syst Rev, 2007(3):CD001240.
［2］Chaudhari T, McGuire W. Allopurinol for preventing mortality and morbidity in newborn infants with suspected hypoxic-ischaemic encephalopathy［J］. Cochrane Database Syst Rev, 2008(2):CD006817.
［3］McGuire W, Fowlie PW, Evans DJ. Naloxone for preventing morbidity and mortality in newborn infants of greater than 34 week' gestation with suspected perinatal asphyxia［J］. Cochrane Database Syst Rev, 2004(1):CD003955.
［4］Hunt R, Osborn D. Dopamine for prevention of morbidity and mortality in term newborn infants with suspected perinatal asphyxia［J］. Cochrane Database Syst Rev, 2002(3):CD003484.
［5］Vargas-Origel A, Espinosa-García JO, Muniz-Quezada E, Vargas-Nieto MA, Aguilar-Garcia G. Prevention of hypoxic-ischemic encephalopathy with high-dose, early phenobarbital therapy［J］. Gac Med Mex, 2004, 140(2):147-153.
［6］Hall RT, Hall FK, Daily DK. High-dose phenobarbital therapy in term newborn infants with severe perinatal asphyxia: a randomized, prospective study with three-year follow-up［J］. J Pediatr, 1998, 132(2):345-348.
［7］Singh D, Kumar P, Narang A. A randomized controlled trial of phenobarbital in neonates with hypoxic ischemic encephalopathy［J］. J Matern Fetal Neonatal Med, 2005, 18(6):391-395.
［8］Ruth V. Neonatal stress or distress［J］. J Perinat Med, 1991, 19（Suppl 1）:151-156.
［9］Goldberg RN, Moscoso P, Bauer CR, Bloom FL, Curless RG, Burke B, et al. Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial［J］. J Pediatr, 1986, 109(5):851-856.
［10］Vela F, Duran JA, Chunga F, Serrano JS, Valls A. Preventive treatment of convulsions in perinatal asphyxia［J］. An Esp Pediatr, 1987, 27(2):95-99.
［11］Van Bel F, Shadid M, Moison RM, Dorrepaal CA, Fontijn J, Monteiro L, et al. Effect of allopurinol on postasphyxial free radical formation, cerebral hemodynamics, and electrical brain activity［J］. Pediatrics, 1998, 101(2):185-193.
［12］Benders MJ, Bos AF, Rademaker CM, Rijken M, Torrance HL, Groenendaal F, et al. Early postnatal allopurinol does not improve short term outcome after severe birth asphyxia［J］. Arch Dis Child Fetal Neonatal Ed, 2006, 91(3):F163-165.
［13］Gunes T, Ozturk MA, Koklu E, Kose K, Gunes I. Effect of allopurinol supplementation on nitric oxide levels in asphyxiated newborns［J］. Pediatr Neurol, 2007, 36(1):17-24.
［14］Ichiba H, Tamai H, Negishi H, Ueda T, Kim TJ, Sumida Y, et al. Randomized controlled trial of magnesium sulfate infusion for severe birth asphyxia［J］. Pediatr Int, 2002, 44(5):505-509.
［15］Adhikari M, Moodley M, Desai PK. Mannitol in neonatal cerebral oedema［J］. Brain Dev, 1990, 12(3):349-351.
［16］Chernick V, Manfreda J, De Booy V, Davi M, Rigatto H, Seshia M. Clinical trial of naloxone in birth asphyxia［J］. J Pediatr, 1988, 113(3):519-525.
［17］DiSessa TG, Leitner M, Ti CC, Gluck L, Coen R, Friedman WF. The cardiovascular effects of dopamine in the severely asphyxiated neonate［J］. J Pediatr, 1981, 99(5):772-776.
［18］Levene MI, Gibson NA, Fenton AC, Papathoma E, Barnett D. The use of a calcium-channel blocker, nicardipine, for severely asphyxiated newborn infants［J］. Dev Med Child Neurol, 1990, 32(7):567-574.
［19］Juul SE, McPherson RJ, Bauer LA, Ledbetter KJ, Gleason CA, Mayock DE. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety［J］. Pediatrics, 2008, 122(2):383-391.
［20］Fauchere JC, Dame C, Vonthein R, Koller B, Arri S, Wolf M, et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants［J］. Pediatrics, 2008, 122(2):375-382.
［21］Calvert JW, Zhang JH. Pathophysiology of an hypoxic-ischemic insult during the perinatal period［J］. Neurol Res, 2005, 27(3):246-260.
［22］Boylan GB, Rennie JM, Chorley G, Pressler RM, Fox GF, Farrer K, et al. Second-line anticonvulsant treatment of neonatal seizures: a videoEEG monitoring study［J］. Neurology, 2004, 62(3):486-488.
［23］Whitelaw A. Systematic review of therapy after hypoxic-ischaemic brain injury in the perinatal period［J］. Semin Neonatol, 2000, 5(1):33-40.
［24］Sulzbacher S, Farwell JR, Temkin N, Lu AS, Hirtz DG. Late cognitive effects of early treatment with phenobarbital［J］. Clin Pediatr (Phila), 1999, 38(7):387-394.
［25］Holmes LB, Coull BA, Dorfman J, Rosenberger PB. The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs［J］. J Pediatr, 2005, 146(1):118-122.
［26］Dessens AB, Cohen-Kettenis PT, Mellenbergh GJ, Koppe JG, van De Poll NE, Boer K. Association of prenatal phenobarbital and phenytoin exposure with small head size at birth and with learning problems［J］. Acta Paediatr, 2000, 89(5):533-541.
［27］Bittigau P, Sifringer M, Genz K, Reith E, Pospischil D, Govindarajalu S, et al. Antiepileptic drugs and apoptotic neurodegeneration in the developing brain［J］. Proc Natl Acad Sci USA, 2002, 99(23):15089-15094.
［28］Jacobs S, Hunt R, Tarnow-Mordi W, Inder T, Davis P. Cooling for newborns with hypoxic ischaemic encephalopathy［J］. Cochrane Database Syst Rev, 2007(4):CD003311.
［29］Roka A, Melinda KT, Vasarhelyi B, Machay T, Azzopardi D, Szabo M. Elevated morphine concentrations in neonates treated with morphine and prolonged hypothermia for hypoxic ischemic encephalopathy［J］. Pediatrics, 2008, 121(4):e844-849.
